ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pitavastatin

Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.

Drug pagePitavastatin: every studyMany companies study it; this page follows only the 29 they lead. All 75 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 18, 200929 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kowa180 open or runningphase 4since Dec 18, 2009Nov 4, 2005none ahead
JW Pharmaceuticalits history only80 open or runningphase 4since Mar 18, 2008Mar 18, 2008none ahead
Merckits history only10 open or runningphase 1since Oct 12, 2017Oct 12, 2017none ahead
Orient Pharmaits history only10 open or runningphase 3since Oct 16, 2012Oct 16, 2012none ahead
Tai Tien Pharmaceuticalsits history only10 open or runningphase 3since Jun 29, 2011Jun 29, 2011none ahead

Also a collaborator on its studies: Orient Europharma, Kowa Pharmaceuticals America and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kowa only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2005First studies: 3 phase 3 studiesFirst studyNCT00249249, NCT00309777, NCT00257686
  2. Dec 8, 20052 phase 3 studiesNCT00309751, NCT00309738
  3. Feb 10, 2006Phase 3 study in HypercholesterolemiaNCT00325780 · 1,355 enrolled · Denmark, Finland, Germany and more
  4. May 26, 2006Phase 3 study in HypercholesterolemiaNCT00330876 · 545 enrolled · Denmark, Germany, Israel and more
  5. Jun 22, 20062 phase 3 studiesNCT00344175, NCT00344370
  6. Dec 18, 2009Phase 4 study in Renal InsufficiencyNCT01043094 · 16 enrolled · United States
  7. Jan 25, 2010Phase 4 study in Healthy VolunteersNCT01057433 · 24 enrolled · United States
  8. Dec 7, 2010Phase 4 study in Primary DyslipidemiaNCT01256476 · 328 enrolled · United States
  9. Feb 18, 2011Phase 4 study in DyslipidemiasNCT01301066 · 252 enrolled · United States
  10. Aug 22, 20112 phase 4 studies in HealthyNCT01422382, NCT01422369
  11. May 2, 2012Phase 1 study in Metabolic SyndromeNCT01595828 · 14 enrolled · United Kingdom
  12. Jan 28, 2016Phase 3 study in HyperlipidemiasNCT02670434 · United States
  13. Jun 10, 2016Phase 3 study in HyperlipidemiasNCT02799758 · United States

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100

Studies

All 18 Kowa leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02799758Hyperlipidemias · United States3WithdrawnJul 20170
NCT02670434Hyperlipidemias · United States3WithdrawnJul 20170
NCT01595828Metabolic Syndrome · United Kingdom1CompletedJun 201214
NCT01422382Healthy · United States4CompletedJun 201128
NCT01422369Healthy · United States4CompletedJun 201128
NCT01301066Dyslipidemias · United States4CompletedMar 2013252
NCT01256476Primary Dyslipidemia · United States4CompletedJun 2011328
NCT01057433Healthy Volunteers · United States4CompletedDec 201024
NCT01043094Renal Insufficiency · United States4CompletedApr 201016
NCT00344370Diabetes Mellitus, Type 2 · Denmark, Germany, India and more3CompletedApr 2008214
NCT00344175Hypercholesterolemia · Denmark, Netherlands, Spain and more3CompletedAug 2007178
NCT00330876Hypercholesterolemia · Denmark, Germany, Israel and more3CompletedDec 2007545
NCT00325780Hypercholesterolemia · Denmark, Finland, Germany and more3CompletedNov 20071,355
NCT00309751Diabetes Mellitus, Type 2 · Denmark, Germany, India and more3CompletedJun 2007418
NCT00309738Hypercholesterolemia · Denmark, Netherlands, Spain and more3CompletedOct 2006355
NCT00257686Hypercholesterolemia · Denmark, Germany, Israel and more3CompletedMay 2006962
NCT00309777Hypercholesterolemia · Finland, Italy, Norway and more3CompletedOct 2006857
NCT00249249Dyslipidemias · Denmark, Finland, Germany and more3Completed830

How it is read

Names in the registry

  • “Pitavastatin”, 18 entries
  • “pitavastatin”, 8 entries
  • “Pitavastatin (NK-104)”, 3 entries
  • “NK-104-CR”, 2 entries
  • “pitavastatin single dose combined with ceftobiprole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.